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Abstract
Electrolyte disorders are a frequent finding in cancer patients. In the majority of 
cases the etiologies of such disorders are common to all cancer types (i.e. diuretic-
induced hyponatremia or hypokalemia). Sometimes, electrolyte disorders are caused 
by paraneoplastic syndromes or are due to cancer therapy. Potassium is one of the 
most important electrolytes of the human body since it is involved in the regulation of 
muscle contraction, maintenance of the integrity of the skeleton, blood pressure and 
nerve transmission as well as in the normal function of cells. Potassium homeostasis 
is strictly regulated since the gap between the recommended daily dietary intake 
(120 mEq/day) and the levels stored in the extracellular fluid (around 70 mEq) is 
huge. Alterations of potassium homeostasis are frequent in cancer patients as well 
alterations in potassium channels, the transmembrane proteins that mediate potas-
sium fluxes within the cells. The present chapter is focused on the clinical significance 
of potassium homeostasis and potassium channels in patients with solid tumors.
Keywords: potassium, electrolyte homeostasis, solid cancers, potassium channels, 
channelopathies
1. Introduction
Potassium has a great importance within the cell as it is one of the main deter-
minants of membrane potential in nervous and muscle cells (both skeletal and 
cardiac). Therefore, it is not surprising that in humans potassium blood levels are 
strictly controlled and even slight deviations from the physiological range can cause 
severe clinical conditions.
The amount of potassium in the human body is 3000–4000 mEq (correspond-
ing to 50–55 mEq/Kg). Potassium levels in the extracellular fluid are quite low 
(roughly 70 mEq corresponding to 2% of the amount absorbed through the intes-
tine) while the majority of K+ (98%) is stored in the body tissues under a tight hor-
monal control. This great gap between extracellular fluid and tissues is responsible 
of the restricted range of K+ levels in the plasma (3.5–5.5 mEq/L) that is maintained 
through the following mechanisms:
• Activity of Na-K ATPase. The Na-K pump actively extrudes three Na+ from 
the cells exchanging them with two K+ that enter the cells against gradient 
[1]. Such mechanism makes it possible the preservation of the physiological 
electrolyte concentration as well as the maintenance of the normal volume of 
extracellular fluid. It is also essential for the solute passage through renal and 
intestinal epithelia.
• Elimination of potassium dietary intake through feces and urine.
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A scheme of potassium intake, absorption and elimination is reported in 
Figure 1.
Potassium intake from diet is mainly due to the consumption of K+-rich food 
such as bananas, avocados, grapes and salmon, among others. Once introduced 
in the body as food, potassium is rapidly conveyed towards intestine, where it 
is absorbed for its majority (90%). It has been suggested that absorption in the 
intestine is a passive process, guided by electrochemical gradients differently from 
the one taking place in the kidney [2].
Insulin is one of the main regulators of potassium homeostasis, modulating 
the exchange between extracellular fluid and tissues such as muscle, through the 
activation of the Na- K ATPase [3]. Moreover, in muscular tissue during exercise, a 
rise in potassium levels causes the stimulation of Na-K ATPase thus enhancing K+ 
uptake [4], although the primary upregulation of the ATPase is due to adrenergic 
stimulation.
From the extracellular fluid, K+ is also conveyed towards kidney where in physi-
ological conditions it is partly reabsorbed and for the major portion eliminated with 
urine (90%) in the distal renal tubule, directed by mineralocorticoids and Na-K 
ATPase. The mechanisms of K+ renal reabsorption are outside the scope of this 
chapter and can be deepened in several reviews (see for example [5]).
K+ distribution across plasma-membranes is regulated by pancreatic hor-
mones, acid–base homeostasis alterations and by the autonomous nervous system. 
Moreover, potassium itself regulates somehow its own excretion and redistribution 
through the stimulation of insulin and aldosterone secretion as well as the increase 
of Na-K ATPase activity in the distal nephron. On the whole, K+ homeostasis is 
due to the interaction of two different systems, one based on K+ cellular uptake 
and the other based mainly on renal excretion and, at a minor extent, on gastro-
intestinal elimination. These two systems have an important difference since the 
Figure 1. 
Schematic diagram of K+ intake, fluxes, storage and elimination.
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redistribution of potassium between intra- and extra-cellular compartments occurs 
rapidly (it takes minutes) while renal response to K+ variations in plasma is quite 
slow (it takes hours to be activated and days to be completed). Moreover, since the 
biological effects depend on the ratio between the external and the internal K+ con-
centration, the regulation of the internal distribution must be extremely efficient. 
A tight association exists between pH and kaliemia, therefore acidosis causes an 
increase of potassium plasma level while alkalosis induces hypokalemia. Another 
pathological condition that might cause hyperkalemia is the increase of osmolarity 
(due to hyperglycemia and hypernatremia).
2. Electrolyte disorders in human cancer
Cancer patients are characterized by complex alterations encompassing the whole 
organism. Among them electrolyte disorders represent quite frequent complications 
in such patients [6, 7] and are mainly due to alterations of sodium, potassium, cal-
cium and magnesium plasma levels. In the majority of the patients these unbalances 
are asymptomatic but in some subjects they can contribute to worsen the clinical 
conditions and therefore must be treated. The electrolyte derangements adversely 
affect survival [8] and can disrupt cancer treatment [9–11]. There are many potential 
causes of electrolyte derangements in cancer patients that might be related either to a 
particular cancer or to any specific therapy. Actually, the picture might be even more 
complicated since these electrolyte disorders can be primary or secondary and active 
treatment can improve prognosis.
3. Potassium homeostasis alterations in human cancer
In cancer patients both a reduction (hypokalemia) or an increase (hyperkalemia) 
in potassium levels might be observed.
Hypokalemia is a condition of low K+ plasma levels (< 3.5 mEq/L) that might 
have different causes in cancer patients. The principal causes of hypokalemia are 
reported in Table 1.
In cancer patients, the main cause of hypokalemia is a reduced K+ intake due to 
malnutrition and malabsorption. In particular cases (i.e. Neuroendocrine Tumors), 
hypokalemia could be provoked by secretive diarrhea that causes potassium losses 
[12, 13]. Other tumors cause hypokalemia with the ectopic secretion of hormones 
(cortisol, ACTH and mineralocorticoids) [14].
In other cases, hypokalemia could be a secondary effect of cancer therapy, since 
some agents might cause diarrhea or vomiting thus leading to K+ loss. Different 
cancer therapy agents (such as cisplatin, anti-EGFR agents and mTOR inhibitors, 
for instance) could induce renal damage associated to hypokalemia due to K+ loss 
caused by tubular toxicity. For this reason, before starting therapy, renal function 
should be evaluated in order to prevent additional renal damage [15].
Also, the simultaneous treatment with different agents (for example thiazide 
diuretics and glucocorticoids) might lead to hypokalemia because they promote 
potassium renal losses. Finally, the concomitant presence of endocrine dysfunctions 
might cause hypokalemia due to glucocorticoids or mineralocorticoids excess [14, 16].
Hyperkalemia is a condition of increased K+ plasma levels (> 5.5 mEq/L). The 
principal causes of hyperkalemia are reported in Table 2.
The main causes of hyperkalemia in cancer patients are represented by reduced 
renal elimination caused by renal failure and redistribution within extracellular 
compartment.
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In cancer patients there are different conditions than can induce hyperkalemia 
[1]. For instance, highly proliferative tumors can develop lysis syndrome after 
anticancer therapy, thus causing hyperkalemia. As in the case of hypokalemia, also 
treatment with chemotherapeutic agents such as platinum compounds might lead 
to hyperkalemia due to renal injury. Patients treated with a combination of drugs 
(i.e. potassium sparing diuretics, NSAIDs, angiotensin-converting enzyme inhibi-
tors) might develop hyperkalemia. Also, the occurrence of concomitant disease (i.e. 
diabetes mellitus, sepsis, renal failure) or the need of parenteral nutrition might 
cause hyperkalemia [17, 18]. An important cause of hyperkalemia is represented by 
Tumor Lysis Syndrome, a serious condition characterized by hyperkalemia, hyper-
phosphatemia, hypocalcemia, hyperuricemia and hyperazotemia (Figure 2).
TLS generally occurs within 72 hours from the therapy beginning and it is 
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The causes primarily represented in cancer patients are indicated in bold.
Table 1. 
Main causes of hypokalemia.
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In particular, there is an increase of potassium, phosphate and uric acid plasma 
levels while calcium levels are reduced. As a consequence, calcium phosphate 
precipitates in renal tubules, thus causing kidney injury and failure. Renal injury 
causes a worsening of metabolic disorders and hyperkalemia that can lead to 
arrhythmias, seizures, weakness and muscle cramps. Some cancer patients have 
a higher risk of developing TLS: for example, patients with a large tumor burden, 
rapidly growing tumors and tumors highly responsive to therapy (either standard 
chemotherapy, hormonal, radiation and targeted therapy). All these factors 
should be carefully evaluated before starting the treatment [20]. TLS gener-
ally occurs after a week of treatment but it can also develop spontaneously, for 
Figure 2. 













The causes primarily represented in cancer patients are indicated in bold.
Table 2. 
Main causes of hyperkalemia.
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example in childhood cancers [21]. Moreover, patients suffering from additional 
renal dysfunctions have a higher risk of developing TLS.
Other causes of hyperkalemia in cancer patients are represented by adrenal 
insufficiency (Addison’s disease) due to metastases in the adrenal gland especially 
in patients with advanced tumor of the breast and lung. Nevertheless, although 
the frequency of adrenal metastases is high, adrenal failure is rare due to the use of 
corticosteroids [22].
3.1 Potassium in paraneoplastic syndromes
According to the National Cancer Institute (NCI, Dictionary of Cancer Terms, 
https://www.cancer.gov/publications/dictionaries/cancer-terms) a paraneoplastic 
syndrome is defined as follows: “A group of symptoms that may develop when 
substances released by some cancer cells disrupt the normal function of surround-
ing cells and tissue”. This definition implies that a cancer patient may develop 
symptoms that are not directly attributable to tumor invasion or compression [23]. 
Paraneoplastic syndromes may have impact on different organs, such as endocrine, 
neurologic, hematologic, rheumatologic and dermatologic systems. Such group of 
disorders may be due to the ectopical secretion of hormones and peptides (endo-
crine paraneoplastic syndromes) or immune cross-reactivity (neurologic paraneo-
plastic syndromes) [24].
The only endocrine paraneoplastic syndrome involving K+ alteration is Cushing 
syndrome, characterized by hypercortisolism [25]. The syndrome is caused by the 
secretion of adrenocorticotropic hormone or corticotropin-releasing factor from 
tumor cells [26, 27] followed by cortisol secretion from the adrenal glands. The 
main features of Cushing syndrome are reported in Table 3.
In contrast to other paraneoplastic syndromes (i.e. syndrome of inappropriate 
antidiuretic hormone secretion and hypercalcemia), patients often develop Cushing 
syndrome’s symptoms before cancer is diagnosed. Moreover, the reappearance of 
Cushing syndrome may precede tumor recurrence [24].
4. Potassium channels
The multi-gene family of potassium channels is made of several subfamilies 
(Figure 3): calcium-activated channels, voltage-gated channels, inward rectifiers 
and two-pore domains (reviewed in [30, 31]).
Calcium-activated potassium channels are represented by two classes of 
proteins: “small- and intermediate- conductance” (SK) and “high-conductance” 
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Main features of Cushing syndrome.
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(BK) potassium channels. SK channels assemble as tetramers and each monomer is 
composed by six transmembrane domains (S1-S6) with a central pore in the S5-S6 
region. Similarly, BK channels are organized as tetramers with α and β subunits; in 
this case the pore is formed by α subunits.
Voltage-gated potassium channels are composed by four subunits (each consti-
tuted by six transmembrane domains termed S1-S6) surrounding an aqueous pore. 
In these channels, the pore (P) is formed by a loop between S5 and S6. S4 domain 
acts as voltage sensor.
Inward rectifier potassium channels are tetramers, with each monomer charac-
terized by only two transmembrane domains linked by a P-loop.
The last subfamily is represented by Two-pore domains channels, made of four 
transmembrane domains with two regions forming the aqueous pores.
4.1 Potassium channels in human cancer
Among ion channels, those selective for K+ channels are the most frequently de-
regulated in cancers. Several reports have been published over the years, highlight-
ing K+ channels’ relevance in human solid cancers [31]. For example, in colorectal 
cancer the presence of the transcripts of KCNA3, KCNA5, KCNC1, KCNH1 [32–34], 
KCNH2 [35] and KCNK9 [36] was reported.
KCa1.1 channels (also indicated as BK channels) are encoded by the KCNMA1 
gene, located in 10q22, and belong to the high conductance subgroup of the calcium-
activated subfamily. For these channels a clinical relevance in breast and prostate 
cancer has been demonstrated [37–41]. In breast cancer, KCNMA1 gene amplification 
occurs in invasive ductal tumors, and it is associated with high grade, high stage and 
unfavorable prognosis [37]. Moreover, KCa1.1 expression positively correlates with 
estrogen receptors [41] and the channel is expressed at higher levels in breast cancers 
developing metastases to brain [38]. Similarly, in prostate cancer KCNMA1 is more 
frequently amplified in late-stage tumors [39] and represents a promising diagnostic 
biomarker since it is over-expressed in tumors with Gleason score equal to 5–6 [40].
KCa3.1, encoded by the KCNN4 gene, is another member of the calcium-
activated subfamily that is frequently upregulated in high grade breast cancers 
[42], small cell lung cancer [43], colorectal cancer [44] and pancreatic ductal 
Figure 3. 
Potassium channels subfamilies.
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adenocarcinomas [45]. In small cell lung cancer, KCNN4 hypomethylation was 
shown to be a negative prognostic factor [43].
Kv1.3 (also named KCNA3) is a channel belonging to the voltage gated subfam-
ily that was shown to be overexpressed in Gleason score 5–6 prostate cancer samples 
with respect to Gleason Score 8–9 patients [46], being down-regulated in high grade 
tumors [47]. In pancreatic cancer Kv1.3 is down-expressed with respect to healthy 
pancreas and such downregulation could be due to the methylation of the promoter 
of the gene and it was also associated with the development of metastases [48].
Kv7.1 (also named KCNQ1) was shown to be over-expressed in lung tumors and 
to regulate cell proliferation and migration [49].
Kv10.1 (KCNH1) was shown to be expressed in esophageal squamous cell carci-
noma and it was proposed as an independent negative prognostic factor [50]. Kv10.1 
is highly expressed also in colorectal cancers where it is associated with lymph node 
metastasis, tumor size, Dukes staging and was therefore proposed as a prognostic 
marker [51]. Also in gastric cancer it was demonstrated that high Kv10.1 expression 
is associated with lymph node metastasis and higher stage [52].
Kv11.1 (KCNH2) was found to be expressed in a high percentage of esophageal 
squamous cell carcinoma samples with respect to healthy esophageal squamous 
epithelium [53]. Similarly, in esophageal adenocarcinomas it was shown that Kv11.1 
as well as the corresponding gene are expressed [54] and more recently it was 
shown that preneoplastic lesions expressing high levels of Kv11.1 have a signifi-
cantly higher risk to progress towards adenocarcinoma [55]. Kv11.1 is also associated 
with TNM stage, grading, serosal and venous invasion, Lauren intestinal type and 
VEGF-A expression in gastric cancer [56, 57]. In colorectal cancers, the overex-
pression of Kv11.1 regulates cell invasion [35]. Moreover, in TNM I and II samples 
Kv11.1 presence associated with Glut-1 absence represents an independent negative 
prognostic factor [58]. More recently, it was shown that the concomitant expression 
of hERG1 and HIF-2α represents a prognostic biomarker and it can be used to select 
metastatic CRC patients suitable to be treated with Bevacizumab [59]. In pancreatic 
cancer Kv11.1 is associated to aggressive behavior and poorer prognosis [60].
Kir3.1 (KCNJ3) channels belong to the inward rectifier subfamily and it was shown 
that they positively correlated with lymph node metastases in breast cancer [61].
Several members of the Two Pore Domain family have been shown to be over-
expressed in human tumors [62]. Quite recently, K2P6.1 (KCNK6) was shown to 
be expressed in breast cancer and to promote proliferation, migration and invasion 
[63]. The gene encoding for K2P9.1 (KCNK9, located on 8q23.4) was proven to 
be amplified in breast cancer [64]. Another member of the same family, K2P5.1 
(KCNK5) is induced by estrogens in ER-positive breast cancer cells [65]. K2p 2.1 is 
overexpressed in prostate cancer, where it regulates cell proliferation [66].
5. Conclusion
Potassium is one of the most important mineral for humans, therefore its 
homeostasis is under tight control. Alterations of potassium homeostasis are fre-
quent in cancer patients as well as alterations in potassium channels, and the clinical 
management of such patients must take into account the possibility for the patient 
of developing hypo- and hyperkaliemia to define a proper protocol of treatment.
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